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An improved high performance liquid chromatography–tandem mass spectrometry (LC–MS/MS) method
has been developed for sensitive and rapid determination of albendazole (ABZ) and its active metabolite,
albendazole sulfoxide (ABZSO), in the positive ionization mode. The method utilized solid phase ex-
traction (SPE) for sample preparation of the analytes and their deuterated internal standards (ISs) from
100 mL human plasma. The chromatography was carried out on Hypurity C18 column using acetonitrile-
2.0 mM ammonium acetate, pH 5.0 (80:20, v/v) as the mobile phase. The assay exhibited a linear re-
sponse over the concentration range of 0.200–50.0 ng/mL for ABZ and 3.00–600 ng/mL for ABZSO. The
recoveries of the analytes and ISs ranged from 86.03%–89.66% and 89.85%–98.94%, respectively. Matrix
effect, expressed as IS-normalized matrix factors, ranged from 0.985 to 1.042 for the both analytes. The
method was successfully applied for two separate studies in healthy subjects using single dose of 400 mg
conventional tablets and 400 mg chewable ABZ tablets, respectively.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Albendazole (ABZ), a benzimidazole derivative, is characterized
as a broad spectrum anthelmintic agent and has shown good
efﬁcacy in the treatment of echinococcosis, hydatid cysts and
neurocysticercosis [1]. It is a hydrophobic drug; therefore, it is
poorly absorbed from the gastrointestinal tract. Further, ABZ is
inconsistently absorbed from the intestine, which is dependent on
the type of food and pH of the stomach [2]. Due to this reason,
several clinical studies have reported signiﬁcant inter-individual
variability to it as a result of low aqueous solubility [3]. After oral
administration, ABZ undergoes rapid hepatic oxidation by liver
microsomal enzymes to its major pharmacologically active meta-
bolite, albendazole sulfoxide (ABZSO) which is responsible for
anthelmintic as well as toxic effects. ABZSO is approximately 70%
bound with plasma protein and is widely distributed throughout
the body. It can be detected in urine, cerebrospinal ﬂuid, liver, bile,
cyst wall and cyst ﬂuid. ABZSO is further transformed intoon and hosting by Elsevier B.V. Th
University.
S. Shrivastav).albendazole sulfone (ABZSO2), which does not possess any an-
thelmintic activity [4]. Due to extensive metabolism, the plasma
concentration of ABZ is found to be very low. Nevertheless, the
pharmacokinetic properties of ABZ have been determined by
measuring its plasma concentration in healthy subjects, patients
and different animal species. Moreover, the plasma concentration
of ABZSO is observed to increase in a dose-dependent manner
following ingestion of fatty food [4,5].
As evident from literature, the techniques of choice for the
analysis of ABZ and/or its metabolites in biological samples
include high performance liquid chromatography with UV [6–10],
ﬂuorescence [11–16] and mass spectrometry detection [17–23]
apart from capillary electrophoresis [24]. Due to rapid conversion
of ABZ into its metabolites, several methods report the determi-
nation of ABZSO and inactive metabolites like ABZSO2 and alben-
dazole 2-aminosulphone (ABZASO2) as racemate or enantiomers
in different biological matrices like human plasma [11,17], sheep
plasma [9,14], human serum [12], sheep spermatozoa and seminal
plasma [13], and bovine plasma [15]. Simultaneous analysis of ABZ
and its metabolites is also addressed in different biological sam-
ples such as human plasma [7, 8, 18, 21, 24], ovine plasma [6],
mouse plasma [10], muscle tissues [19], turkey plasma [16], ratis is an open access article under the CC BY-NC-ND license
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plasma [23]. Only two methods are reported for the simultaneous
determination of ABZ and ABZSO in human plasma by liquid
chromatography–tandem mass spectrometry (LC–MS/MS) method
[18,21]. Chen et al. [18] developed an assay with the linear con-
centration range of 0.4–200 ng/mL for ABZ and 4.0–2000 ng/mL
for ABZSO using liquid–liquid extraction (LLE). The method re-
quired 500 mL plasma samples and the analysis time was 5.0 min.
The other reported method was more rapid (4.0 min) and required
lower plasma volume (200 mL) for processing, but it was less
sensitive (ABZ: 5 ng/mL and ABZSO: 10 ng/mL) [21]. Both the
methods were applied to a pharmacokinetic study in healthy
subjects using 400 mg ABZ.
The aim of the present study was to develop a sensitive, se-
lective and rapid LC–MS/MS method for the simultaneous de-
termination of ABZ and ABZSO in human plasma for clinical stu-
dies. The proposed method is practically free from matrix inter-
ference and is successfully applied for bioequivalence studies in
healthy subjects with 400 mg conventional tablets and 400 mg
(2200 mg) chewable tablets, respectively.2. Experimental
2.1. Chemicals and materials
Albendazole (ABZ, purity: 99.6%) and albendazole sulfoxide
(ABZSO, purity: 99.99%) were purchased from Vivan Life Sciences
Pvt. Ltd. (Mumbai, India). Albendazole-d3 (ABZ-d3, purity: 99.30%)
was procured from Clearsynth Labs Limited (Mumbai, India) while
albendazole sulfoxide-d5 (ABZSO-d5, purity: 99.30%) was obtained
from Syncom (Mumbai, India). HPLC-grade methanol (MeOH) and
acetonitrile (ACN) were procured from J.T. Baker Inc. (Phillipsburg,
NJ, USA). Bioultra grade ammonium acetate (AA) and acetic acid
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Solid
phase extraction (SPE) cartridges, StrataTM-X (30 mg/1.0 mL), were
purchased from Phenomenex India (Hyderabad, India). Water was
puriﬁed using Milli-Q water puriﬁcation system from Millipore
(Bangalore, India). Blank human blood was collected with Na he-
parin as anticoagulant from healthy and drug free volunteers.
Plasma was separated by centrifugation at 2061 g at 10 °C and
stored at 70 °C.
2.2. Liquid chromatography (LC) and mass spectrometry (MS) op-
erating conditions
A Shimadzu HPLC system (Kyoto, Japan) with a Hypurity C18
(50 mm4.6 mm, 5 μm) column from Thermo Scientiﬁc (Che-
shire, UK) was used for chromatographic separation of the ana-
lytes. The column temperature was maintained at 40 °C. The mo-
bile phase consisted of ACN and 2.0 mM AA in water (pH 5.0, ad-
justed with acetic acid in 80:20 (v/v)). For isocratic elution, the
ﬂow rate of the mobile phase was set at 0.5 mL/min. The auto-
sampler temperature was maintained at 5 °C, injection volume
was kept at 2 μL, and the pressure of the systemwas maintained at
450 psi. The LC system was connected to a triple quadrupole massTable 1
Optimized mass parameters and MRM transitions for albendazole, albendazole sulfoxid
Analytes Quadrupole 1 mass
(amu)
Quadrupole 2 mass
(amu)
Dwell time
(ms)
Albendazole 266.1 234.1 200
Albendazole sulfoxide 282.1 240.0 200
Albendazole-d3 269.1 234.1 200
Albendazole sulfoxide-d5 287.1 241.1 200spectrometer MDS SCIEX API-5500 (Toronto, Canada), equipped
with electrospray ionization (ESI) and operated in positive ioni-
zation mode. The optimized source parameters for the analytes
and internal standards (ISs, including ABZ-d3 and ABZSO-d5) were
set as follows: ion spray voltage, 2500 V; curtain gas, 43 psi; Gas 1,
50 psi; Gas 2, 60 psi; turbo heater temperature, 450 °C; collision
activation dissociation, 7 psi. The compound dependent mass
parameters and multiple reaction monitoring (MRM) transitions
used for quantitation of analytes and ISs are summarized in
Table 1. Analyst classic software version 1.5.2 was used to control
all parameters of LC and MS.
2.3. Calibration standards and quality control samples
Stock solutions of ABZ (0.2 mg/mL) and ABZSO (1.0 mg/mL)
were prepared by dissolving accurately weighed amounts in me-
thanol. Calibration standards (CSs) and quality control (QC) sam-
ples were made by spiking blank plasma with appropriate vo-
lumes of working solutions prepared from intermediate stock so-
lutions for both the analytes. The ﬁnal CS concentrations were
0.200, 0.400, 1.20, 5.00, 10.00, 20.0, 30.0, 42.5 and 50.0 ng/mL for
ABZ; 3.00, 6.00, 18.0, 60.0, 120, 240, 360, 510 and 600 ng/mL for
ABZSO, respectively. The QC samples were prepared at ﬁve levels,
i.e., 0.200/3.00 ng/mL (lower limit of quantiﬁcation quality control
(LLOQ QC)), 0.600/9.00 ng/mL (low quality control (LQC)), 6.50/
78.0 ng/mL (medium quality control-1 (MQC-1)) , 16.0/192 ng/mL
(medium quality control-2 (MQC-2)) and 40.0/480 ng/mL (high
quality control (HQC)) for ABZ/ABZSO, respectively.
Separate stock solutions (20.0 mg/mL for ABZ-d3 and
100.0 mg/mL for ABZSO-d5) of ISs were prepared by dissolving
accurately weighed amounts in methanol. Their combined work-
ing solution (ABZ-d3: 10.00 ng/mL and ABZSO-d5: 500 ng/mL) was
prepared from their stock solutions in methanol:water (60:40, v/
v). Standard stock and working solutions used for spiking were
stored at 2–8 °C until use, while CSs and QC samples in plasma
were kept at 70 °C.
2.4. Extraction procedure
Prior to extraction, all frozen subject samples, CSs and QC
samples were thawed and allowed to equilibrate at room tem-
perature. An aliquot of 100 mL of spiked plasma sample/ subject
sample was fortiﬁed with 25 mL of combined working solution of
ISs and vortexed for 10 s. Further, 100 mL of 2 mM AA solution in
water was added, vortexed for another 60 s and centrifuged at
13148 g for 5 min at 10 °C. Extraction of analytes and ISs was
performed on Phenomenex StrataTM-X (30 mg/mL) cartridges
which were pre-treated sequentially with 1.0 mL of methanol
(MeOH) and 1.0 mL of water. The plasma matrix was drained from
the cartridges by applying positive nitrogen pressure. The car-
tridges were washed twice with 1.0 mL of 10% (v/v) MeOH in
water, and the analytes and ISs were eluted with 1 mL of mobile
phase. The samples were brieﬂy vortexed and 2 mL of the eluent
was used for injection into the chromatographic system.e and their internal standards.
Declustering potential
(V)
Entrance poten-
tial (V)
Collision energy
(eV)
Collision cell exit
potential (V)
70.00 10.00 27.00 16.00
85.00 10.00 18.00 17.00
70.00 10.00 27.00 16.00
80.00 10.00 18.00 15.00
Fig. 1. Representative MRM chromatograms of albendazole in (A) double blank plasma (without analyte and IS), (B) blank plasma with working solution of IS, (C) LLOQ
sample and IS, and (D) subject sample at Cmax and IS after oral administration of 400 mg of conventional albendazole tablet.
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The validation of the method was in accordance with the
United States Food and Drug Administration (USFDA) guidelines
[25] and was performed as discussed in our previous report [26].
The detailed procedures and their acceptance criteria are briefed
in Supplementary material.
2.6. Bioequivalence study and incurred sample reanalysis (ISR)
The study design was an open label, randomized, balanced,
crossover, two-treatment, two-period and two-sequence bioequi-
valence design between a single dose of (i) 400 mg of albendazole
conventional tablets (Generic Company, India) with a reference
tablet formulation, ALBENZA
s
(Albendazole, 2200 mg) from
Amedra Pharmaceuticals LLC, USA and (ii) 2200 mg of alben-
dazole chewable tablets (Generic Company, India) with a corre-
sponding reference product, ALBENZA
s
(Albendazole, 2200 mg)
chewable tablet from GlaxoSmithKline, Mississauga, Ontario,Canada in 51 healthy adult Indian subjects under fasting. The
subjects were informed about the objectives and a written consent
was given. The work was subject to review by an independent
ethics committee constituted as per Indian Council of Medical
Research (ICMR), India, which approved the study protocol. Both
the studies were accomplished following International Conference
on Harmonization, E6 Good Clinical Practice guidelines [27]. The
subjects were orally administered with a single dose of test and
reference formulation with 240 mL of water after a recommended
wash out period of 7 days. Blood samples were collected at 0.00
(pre-dose), 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00,
4.33, 4.67, 5.00, 5.50, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 48.00
and 72.00 h after oral administration of test and reference for-
mulations in labeled Na heparin-vacuettes. Plasma was separated
by centrifugation and kept frozen at 70 °C until analysis. During
study, subjects had a standard diet while water intake was un-
monitored. The pharmacokinetic parameters of ABZ and ABZSO
were estimated using SAS software version 9.2.
The assay reproducibility was checked by reanalyzing of 168
Fig. 2. Representative MRM chromatograms of albendazole sulfoxide in (A) double blank plasma (without analyte and IS), (B) blank plasma with working solution of IS
(C) LLOQ sample and IS, and (D) subject sample at Cmax and IS after oral administration of 400 mg of conventional albendazole tablet.
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and the elimination phase in the pharmacokinetic proﬁle of the
drug from each study. The results were compared with initial
pharmacokinetic analysis using the same procedure. As per the
acceptance criteria at least two-thirds of the original results and
repeat results should be within 20% of each other [28].3. Results and discussion
3.1. LC–MS/MS method development
During method development, the ionization of the both ana-
lytes and ISs was accomplished in the positive ESI mode as the
both drugs are basic in nature due to the presence of secondary
amino groups. The full scan Q1 MS spectra for ABZ, ABZSO, ABZ-d3
and ABZSO-d5 predominantly contained protonated precursor
[MþH]þ ions at m/z 266.1, 282.1, 269.1 and 287.1, respectivelyunder the optimized chromatographic conditions. Fragmentation
was initiated using sufﬁcient nitrogen for collision activated dis-
sociation to obtain major product ions at m/z 234.1, 240.0, 234.1
and 241.1, respectively by applying 27 eV collision energy (CE) to
break the precursor ions of ABZ and ABZ-d3, and 18 eV CE for
ABZSO and ABZSO-d5 ions, respectively. The identical product ion
(m/z 234.1) formed for ABZ and ABZ-d3 can be ascribed to the
neutral loss of MeOH and deuterated MeOH, respectively. How-
ever, the fragment ion at m/z 240.0 for ABZSO was different from
that at m/z 241.1 for ABZSO-d5 by one mass unit (Supplementary
Fig. 1). Nonetheless the both the fragments were attributed to the
neutral loss of propylene from the precursor ions via cleavage of
carbon-sulfur bond. Similar observation was also reported by
Zhang et al. [19] using ABZSO-d3 as the IS. Further, in addition to
the quantiﬁer ion, one qualiﬁer ion was also selected for un-
ambiguous proof of the analytes. For mass spectral identity, a
qualifying transition of m/z 266.1-191.1 for ABZ and m/z 282.1-
222.0 for ABZSO was also monitored. Cross talk, a memory effect of
Fig. 3. Post column analyte infusion MRM chromatograms of (A) albendazole and albendazole-d3 and (B) albendazole sulfoxide and albendazole sulfoxide-d5 at ULOQ
concentration.
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other precursor-product ion channels, was also studied. The re-
sults of the cross talk experiment showed no measurable change
in the peak area of ABZ and its IS which share an identical product
ion at their respective MRMs.
Chromatographic conditions were optimized to achieve a short
runtime, adequate retention, acceptable peak shapes and baseline
separation of the drugs. Due to difference in the hydrophobic
character of ABZ and ABZSO, three different columns, namely
Hypurity C18, Hypurity C8 and Hypurity Advance, having identical
dimensions (50 mm4.6 mm, 5 μm) and pore size (190 Å) but
different carbon loading of 13%, 8% and 10%, respectively, were
tested. Mobile phase composition of MeOH/ACN and AA buffer
(1.0–8.0 mM) was optimized by varying the ﬂow rate from 0.30 to
1.0 mL/min and changing the pH of the buffer from 3.0 to 6.0.
Although the baseline separation of analytes was possible on all
three columns, the peak shape was not acceptable on Hypurity C8
and Hypurity Advance columns. Moreover, the response of ABZSO
was not adequate on Hypurity Advance column, while a small
tailing was observed for ABZ. Thus, different composition of the
organic diluents and the aqueous part (90:10, 85:15, 80:20, 70:30
and 60:40, v/v) were tested on Hypurity C18 column. Finally, the
best separation for the analytes with adequate response and better
peak shape was achieved with ACN and 2.0 mM ammonium
acetate (pH 5.0, adjusted with acetic acid) in 80:20 (v/v) as the
mobile phase at a ﬂow rate of 0.5 mL/min. Under the optimized
conditions, the analytes were baseline-resolved with a resolution
factor of 1.1 within 2.5 min. The representative chromatograms in
Figs. 1 and 2 show no interference of endogenous compounds at
the retention time of ABZ and ABZSO for samples spiked at LLOQ
concentration and subject samples at Cmax. Further, the reprodu-
cibility (%CV) in the measurement of retention time for the ana-
lytes was r0.5% for 90 injections. There was no interference of
commonly used medications by subjects at the retention time of
the analytes. Post column infusion chromatograms further sub-
stantiate the absence of matrix effects with no signal enhance-
ment or suppression at the retention time of ABZ, ABZSO and their
deuterated analogs (Fig. 3).
Several methods have utilized LLE for the simultaneous de-
termination of ABZ and its metabolites [18,19,22]. Mainly mixed
solvent systems have been used due to the difference in theionization constants (basic nitrogen, pKa 2.8 (ABZ) and 3.5
(ABZSO) and acidic nitrogen, pKa 10.3 (ABZ) and 9.8 (ABZSO))
and lipophilicity of ABZ (log P 3.14) and ABZSO (log P 0.97) [9].
Initially, protein precipitation was tried using 10% tetrahydrofuran
in ACN as reported by Sharma et al. [20]. However, the recovery
was inconsistent, mainly at the LLOQ and LQC concentration of the
analytes. Thereafter, LLE was initiated using binary and ternary
combination of n-hexane, methyl tert-butyl ether, ethyl acetate
and dichloromethane. In all the solvent mixtures, the recovery
found was in the range of 62%–78% for both the analytes. Notice-
ably, in few of the samples, the extracts became slightly turbid
after about 30 min at room temperature. Thus, SPE was tested on
different extraction cartridges like Phenomenex Strata-X, Oasis
HLB and Lichrosep DVB HL. Under identical conditions of washing
and analyte elution, Phenomenex Strata-X provided superior re-
covery for both the analytes in comparison to the other two car-
tridges and hence was selected in the present work. Further, it was
observed that initial dilution of the plasma sample (100 mL) with
100 mL of 2 mM AA solution was necessary to get adequate re-
sponse and consistency in the recovery of ABZSO. In the absence of
AA solution, there was inconsistent retention of ABZSO, mainly at
higher concentration. The role of washing solution (10%, 20%, 30%
and 40% MeOH in water) was also critically examined and it was
found that 10% MeOH gave highly consistent and quantitative re-
coveries for both the analytes at ﬁve QC levels. With higher pro-
portion of methanol, there was some loss in the recovery of
ABZSO. The extracts thus obtained were directly used for injection
into the chromatographic system without drying and reconstitu-
tion unlike previous study employing SPE [7].
A comparative assessment of all LC–MS/MS based methods for
the simultaneous determination of ABZ and ABZSO is summarized
in Table 2. The present method is highly sensitive and rapid
compared to all existing methods for ABZ and ABZSO in different
biological ﬂuids [18,20–22] except one method [19]. However, that
method was focused on the analysis of ABZ and its metabolites
from ﬁsh tissue samples (2.0 g). Another important aspect of the
newly developed method was the use of very low human plasma
volume for processing and much shorter analysis time compared
to these methods.
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Table 3
Extraction recovery for albendazole and albendazole sulfoxide.
Quality control
level
Area response (n¼6) Extraction
recovery (%)
Pre-extraction
spiking
Post-extraction
spiking
Albendazole
LQC 33840 38328 88.29
MQC-1 361753 415092 87.15
MQC-2 909848 1021957 89.03
HQC 2226462 2543946 87.52
Albendazole sulfoxide
LQC 26465 30762 86.03
MQC-1 236036 266707 88.50
MQC-2 582621 656099 88.80
HQC 1620905 1807835 89.66
Albendazole-d3
LQC 275014 277960 98.94
MQC-1 259290 269897 96.07
MQC-2 271688 276274 98.34
HQC 256789 265251 96.81
Albendazole sulfoxide-d5
LQC 302504 322396 93.83
MQC-1 284407 312604 90.98
MQC-2 288423 314803 91.62
HQC 310593 345679 89.85
Extraction recovery: pre-extraction spiking/post-extraction spiking.
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The column and autosampler carryover experiment showed
minimal carryover in blank plasma (r0.56% of LLOQ sample for
ABZ and ABZSO) after subsequent injection of upper limit of
quantitation (ULOQ) sample under the optimized conditions. ABZ
and ABZSO gave a linear response (r2Z0.9976) for the established
concentration range of 0.200-50 ng/mL and 3.00–600 ng/mL, re-
spectively. The mean linear equations for calibration curve con-
centrations were y¼(0.4010070.01229)xþ(0.0024770.00227)
and y¼(0.0094070.00010)xþ(0.0023370.00134) for ABZ and
ABZSO respectively. According to the linear regression model used
with 1/x2 weighting, the accuracy of the back calculated con-
centration ranged from 91.93% to 104.87% and the precision (%CV)
varied from 0.11% to 3.52% for both the analytes. The signal-to-
noise ratio was Z28 at the LLOQ concentration for ABZ and
ABZSO.
The intra and inter-day precision ranged from 1.11% to 6.64%
and the accuracy varied from 95.40% to 105.59% for the analytes
(Supplementary Table 1). The mean relative recoveries determined
by comparing the absolute signal of blank plasma samples spiked
before and after extraction at four QC levels were 88.00% and
88.25% for ABZ and ABZSO, respectively. Similarly, the mean re-
coveries for ABZ-d3 and ABZSO-d5 were 97.54% and 91.57%, re-
spectively (Table 3). Absolute matrix effects expressed as matrix
factors at LQC and HQC levels are given in Table 4. The IS-nor-
malized matrix factors ranged from 0.985 to 1.042 for the both
analytes. Relative matrix effect was also evaluated at LQC and HQC
levels in Na-heparin plasma, lipemic and haemolysed plasma
sources. The precision (%CV) in the measurement of ABZ and
ABZSO concentration at these levels ranged from 1.15% to 2.17% for
the both analytes as shown in Supplementary Table 2.
The stock solutions of the analytes and ISs in MeOH kept for
short-term (at 25 °C) and long-term (at 5 °C) stability tests were
found unchanged up to 17 h and at least 13 days, respectively. The
bench-top stability of the analytes in plasma was established up to
16 h. Both ABZ and ABZSO were stable (within 76% of initial
concentration) during ﬁve freeze-thaw cycles at 70 °C and for at
least 50 h in the autosampler. Processed sample stability of the
Table 4
Matrix factors for albendazole and albendazole sulfoxide in human plasma (n¼6).
Analyte Mean area response Matrix factor IS-normalized matrix factor
Post-extraction spiking Neat samples in mobile phase
LQC HQC LQC HQC LQC HQC LQC HQC
Albendazole 38328 2543946 41235 2775184 0.930 0.917 1.009 0.986
Albendazole-d3 277960 265251 301444 285178 0.922 0.930 – –
Albendazole sulfoxide 30762 1807835 32077 1843428 0.959 0.981 1.042 0.985
Albendazole sulfoxide-d5 322396 345679 350468 347008 0.920 0.996 – –
Matrix factor: post-extraction spiking/neat samples in mobile phase.
Table 5
Stability results for albendazole and albendazole sulfoxide under different conditions
(n¼6).
Storage condition QC level Albendazole Albendazole sulfoxide
Accuracy (%) CV (%) Accuracy (%) CV (%)
Bench-top stability;
16 h, 25 °C
LQC 103.21 1.04 104.23 2.44
HQC 96.21 1.08 96.23 1.63
Freeze and thaw
stability; 5 cycles,
70 °C
LQC 99.46 5.03 104.79 5.43
HQC 93.94 3.92 94.01 3.20
Auto-sampler
stability; 50 h,
5 °C
LQC 103.57 1.72 104.75 2.61
HQC 96.31 1.54 95.34 2.05
Processed sample
stability; 17 h,
25 °C
LQC 103.39 3.11 101.55 2.27
HQC 97.17 1.07 96.01 1.11
Long-term stability
in plasma; 139
days, 70 °C
LQC 105.00 4.76 102.45 3.11
HQC 103.88 5.78 99.06 2.16
Fig. 4. Mean plasma concentration–time proﬁles of albendazole and albendazole sulf
formulation and (B) 400 mg (2200 mg) of chewable albendazole tablet formulations
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ples stored at 70 °C for long-term stability experiment were
found stable for a minimum period of 139 days. The detailed sta-
bility results are presented in Table 5.
The precision (%CV) and accuracy values to prove the ruggedness of
the method with different columns and analysts ranged from 3.75% to
6.12% and 95.60% to 104.81%, respectively, for ABZ and ABZSO across
ﬁve QC levels. Similarly, the %CV and accuracy in establishing the di-
lution reliability of 1/2th and 1/4th dilution varied from 2.86% to 4.19%
and 92.8% to 102.7%, respectively, for the both analytes.
3.3. Application of the method and ISR results
To the best of our knowledge, there have been no reports on the
pharmacokinetics of ABZ in healthy Indian subjects. The present study
was undertaken to evaluate the pharmacokinetics of single dose of
400 mg of conventional ABZ tablet formulation and 400mg
(2200 mg) of chewable ABZ tablet formulation. The mean proﬁles
obtained for ABZ and ABZSO after oral administration of test andoxide after oral administration of (A) 400 mg of conventional albendazole tablet
to 51 healthy Indian subjects.
Table 6
Pharmacokinetic parameters (mean7SD) following oral administration of different albendazole tablet formulations to 51 healthy Indian subjects under fasting.
Parameter Albendazole Albendazole sulfoxide
Test Reference Test Reference
Single 400 mg conventional tablet
Cmax (ng/mL) 11.1475.01 11.4974.43 193.50752.87 207.06759.55
Tmax (h) 1.9470.82 2.0771.60 3.1871.45 3.1372.22
t1/2 (h) 4.5371.24 5.1371.26 15.8174.63 17.0373.34
AUC0-72h (h ng/mL) 51.97738.44 53.43736.00 3049.7171721.07 3306.3271771.49
AUC0-inf (h ng/mL) 64.68741.84 67.61739.68 3474.9571776.46 3805.6872236.19
Kel (1/h) 0.14970.026 0.13770.043 0.04970.018 0.04570.015
2200 mg chewable tablet formulation
Cmax (ng/mL) 9.5574.76 10.0675.04 198.19730.17 192.53727.87
Tmax (h) 2.2371.26 2.1971.22 2.8970.99 3.0070.67
t1/2 (h) 5.8372.07 5.6872.58 16.0575.01 15.9874.65
AUC0-72h (h ng/mL) 53.02725.01 60.22728.11 3203.8071647.21 3068.3271671.05
AUC0-inf (h ng/mL) 66.4976.46 75.38741.97 3501.3071662.43 3386.8071713.15
Kel (1/h) 0.11670.053 0.11970.034 0.05070.018 0.05270.020
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Fig. 4. It was evident from the mean pharmacokinetic parameters that
there was no signiﬁcant difference between the conventional and
chewable tablet formulations for the both analytes in any parameter
(Table 6). However, except for the time point of maximum plasma
concentration (Tmax) values, there was little correlation between other
parameters from the studies conducted in Chinese [18] or Caucasian
healthy subjects [21] with identical dose strength. The Cmax values
obtained for ABZ and ABZSO were 96.4 and 635 ng/mL in Chinese
subjects and 57.49 and 829.95 ng/mL in Caucasian subjects, respec-
tively. It was observed that Cmax for the both analytes in the Indian
subjects was much lower than these values. Similar observation was
noted for the area under the plasma concentration vs time curve from
zero hour to 72 h (AUC0–72h) values for ABZ and ABZSO. These sig-
niﬁcant differences in the pharmacokinetic parameters can be at-
tributed to age, gender (body size and muscle mass) and ethnicity,
which have clinically relevant effects. Nevertheless, the large inter-
individual variation in the pharmacokinetic parameters observed is
consistent with both these studies [18, 21]. Further, the reproduci-
bility of the developed method was conﬁrmed by reanalysis of 168
incurred samples for each study (total 336). The % change in the
concentration of both the analytes was within 717% from the initial
pharmacokinetic results for both the studies.4. Conclusions
A new sensitive and rapid method has been developed for the
simultaneous determination of ABZ and its active metabolite
ABZSO in human plasma. Compared to the existing methods in
plasma samples, the present method has the advantages of high
throughput, sensitivity, and small plasma volume for processing.
The method has shown adequate consistency to analyze ABZ and
ABZSO in clinical samples with acceptable accuracy and precision.
The method was extensively validated according to FDA guidelines
and showed good reproducibility as evident from the results of
incurred sample reanalysis. The optimized extraction procedure
ensured clear samples for direct injection without drying and re-
constitution steps. The recovery of the analytes was good with
minimal matrix interference.Acknowledgments
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